Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Our job is to evaluate you honestly, explain what the evidence says, and recommend a plan only if the potential benefits outweigh the risks for you as an individual patient
Sanders KM, Kotowicz MA, Nicholson GC
Dahabiyeh LA, Mahmoud NN, Al-Natour MA, Safo L, Kim D-H, Khalil EA
Phase II results of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA) phase II/III study
These sound alarming, but they are almost always transient and mild
doi:10.1177/0300060518786918
US$ 21.97
US$ 25.16
US$ 24.64
US$ 28.04
